HomeCompareTVAL vs MRK

TVAL vs MRK: Dividend Comparison 2026

TVAL yields 1.12% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $9.5K in total portfolio value
10 years
TVAL
TVAL
● Live price
1.12%
Share price
$36.18
Annual div
$0.41
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.3K
Annual income
$120.72
Full TVAL calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — TVAL vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTVALMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TVAL + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TVAL pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TVAL
Annual income on $10K today (after 15% tax)
$95.41/yr
After 10yr DRIP, annual income (after tax)
$102.61/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $705.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TVAL + MRK for your $10,000?

TVAL: 50%MRK: 50%
100% MRK50/50100% TVAL
Portfolio after 10yr
$26.0K
Annual income
$535.51/yr
Blended yield
2.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TVAL
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TVAL buys
0
MRK buys
0
No recent congressional trades found for TVAL or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTVALMRK
Forward yield1.12%3.25%
Annual dividend / share$0.41$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$21.3K$30.7K
Annual income after 10y$120.72$950.29
Total dividends collected$1.2K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TVAL vs MRK ($10,000, DRIP)

YearTVAL PortfolioTVAL Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,812$112.24$11,192$351.54$380.00MRK
2$11,683$113.42$12,524$392.70$841.00MRK
3$12,615$114.53$14,015$438.65$1.4KMRK
4$13,613$115.58$15,682$489.96$2.1KMRK
5$14,683$116.57$17,547$547.23$2.9KMRK
6$15,828$117.51$19,632$611.16$3.8KMRK
7$17,055$118.38$21,963$682.53$4.9KMRK
8$18,368$119.21$24,571$762.18$6.2KMRK
9$19,773$119.99$27,486$851.08$7.7KMRK
10$21,278$120.72$30,745$950.29$9.5KMRK

TVAL vs MRK: Complete Analysis 2026

TVALStock

The fund seeks to provide long-term capital growth.

Full TVAL Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this TVAL vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TVAL vs SCHDTVAL vs JEPITVAL vs OTVAL vs KOTVAL vs MAINTVAL vs JNJTVAL vs ABBVTVAL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.